Acute exacerbation of chronic obstructive pulmonary disease as a short-term cardiopulmonary risk window: a time-stratified systematic review and meta-analysis Authors: Junsong Xu, Bingchen Zhang, Ran Meng, Wei Zheng, Yuquan Wu Published: 2026 ABSTRACT AbstractBackgroundAcute exacerbations of chronic obstructive pulmonary disease (COPD) are often managed as discrete respiratory events, but patients may enter a short period of systemic cardiopulmonary vulnerability during recovery. We performed a systematic review and meta-analysis to define the timing and magnitude of serious cardiovascular risk after COPD exacerbation.MethodsPubMed, Embase, Scopus, and Web of Science were searched from database inception to April 2026. The review was registered in PROSPERO (CRD420261384390) and followed PRISMA guidance. Eligible studies evaluated cardiovascular outcomes after acute COPD exacerbation using time-defined follow-up windows. Adjusted hazard ratios (HRs) were prioritized for quantitative synthesis. Random-effects meta-analysis used restricted maximum likelihood with Hartung-Knapp adjustment, prediction intervals, time-windowed analyses, and leave-one-study-out sensitivity analyses. Biomarker-only, diagnostic-only, conference-only, and studies without a post-exacerbation cardiovascular outcome were excluded from the primary clinical synthesis. Risk of bias was assessed independently by two reviewers using Newcastle-Ottawa Scale domains.ResultsForty-three studies met inclusion criteria, and 9 studies contributed to the primary 30-day synthesis. COPD exacerbation was associated with increased serious cardiovascular risk within 30 days [pooled HR =2.38, 95% confidence interval (CI): 1.68–3.39]. The highest relative risk was observed during the first week after exacerbation (HR =12.53, 95% CI: 4.93–31.85; k =5), and the 30-day signal persisted after excluding first-week-only estimates (HR =2.13, 95% CI: 1.57–2.88; k =8). Leave-one-study-out analyses did not eliminate the association, although heterogeneity and prediction intervals were substantial. The evidence was predominantly observational or post hoc, and very early estimates were also susceptible to diagnostic overlap. A single aggregate participant count was not calculated because several structurally related cohorts could overlap.ConclusionsAcute COPD exacerbation appears to mark a time-dependent cardiopulmonary risk window rather than an isolated respiratory event. Recent exacerbation should be considered a pragmatic trigger for short-term cardiovascular risk review, particularly after severe or hospitalized exacerbations, while current evidence does not support uniform pharmacologic escalation for all patients.Keywords: Chronic obstructive pulmonary disease (COPD), acute exacerbation, cardiovascular events, systematic review, meta-analysis Highlight box Key findings • Acute exacerbation of chronic obstructive pulmonary disease (COPD) was associated with a marked, time-dependent increase in serious cardiovascular event risk. The relative risk was highest during the first week, but the 30-day association persisted after excluding first-week-only estimates. What is known and what is new? • Cardiovascular disease is common in COPD, and exacerbations may precipitate systemic stress. • This review adds a time-windowed synthesis showing that a recent exacerbation is most useful as a short-term cardiopulmonary safety signal rather than as a uniform long-term risk multiplier. What is the implication, and what should change now? • Severe or hospitalized COPD exacerbation should prompt targeted cardiovascular risk review during early recovery, especially in patients with known cardiovascular disease or persistent symptoms. The evidence supports structured risk assessment, not automatic pharmacologic escalation for all patients. Introduction An acute exacerbation of chronic obstructive pulmonary disease (COPD) is a frequent reason for urgent consultation, hospitalization, and early readmission. In routine pulmonology practice, the immediate priorities are infection control, bronchospasm, gas exchange, inhaled treatment, corticosteroids, antibiotics, oxygenation, and prevention of recurrent exacerbation. Yet the same episode can coincide with systemic inflammation, hypoxemia, sympathetic activation, and decompensation of pre-existing cardiopulmonary disease. For this reason, the recovery period after exacerbation may be clinically important even when respiratory symptoms begin to improve (1-7). The unresolved question is not whether cardiovascular comorbidity is common in COPD. That is already well established. The more actionable question is whether an acute exacerbation identifies a time-limited window in which serious cardiovascular events are more likely and therefore worth actively looking for. Earlier studies described increased myocardial infarction and stroke after exacerbation, and more recent multinational cohort studies have reported temporal clustering of serious cardiovascular events after moderate or severe COPD exacerbations (5,8-18). Two recent systematic reviews and meta-analyses reached similar conclusions and emphasized both the steep early risk trajectory and the sustained excess cardiovascular risk after exacerbation (19,20). These data are difficult to translate into practice because estimates differ by exacerbation severity, comparator period, outcome definition, and follow-up window. This review was designed to make the evidence more usable for clinicians managing thoracic disease, including respiratory and cardiovascular risk after COPD exacerbation. We used a prespecified time-windowed hierarchy, prioritized adjusted hazard ratios (HRs) for serious cardiovascular or major adverse cardiovascular event (MACE)-equivalent outcomes, separated the acute first-week signal from the more clinically actionable 30-day period, and reported prediction intervals to avoid overinterpreting one pooled number. Non-pooled studies and biological evidence were used to explain mechanisms, recurring clinical themes, and potential pathways without being forced into an inappropriate quantitative model. Two features make this question clinically distinct from general COPD-comorbidity reviews. First, the relevant exposure is not stable COPD but a recent exacerbation, which may combine respiratory deterioration, infection or inflammation, temporary medication changes, reduced mobility, and diagnostic uncertainty. Second, the timing of cardiovascular events matters. A risk signal concentrated in the first week has different implications from a risk signal persisting through 30 days or beyond. The present review therefore treats time as a central variable rather than as a background subgroup. We present this article in accordance with the PRISMA reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1634/rc) (21,22). Methods Protocol and reporting The protocol was registered in PROSPERO (CRD420261384390). The review question focused on adults with COPD who experienced moderate, severe, hospitalized, or clinically treated exacerbations and had subsequent cardiovascular outcomes reported within defined follow-up windows. Because the review synthesized previously published aggregate data, institutional ethics approval was not required. The PROSPERO record was amended to clarify that this article reports the COPD-focused quantitative synthesis from the broader registered review because evidence for asthma and bronchiectasis exacerbations was sparse and unsuitable for quantitative pooling; the original review question, eligibility framework, review team, and core methods were unchanged. Search strategy and study selection PubMed, Embase, Scopus, and Web of Science were searched from database inception to April 2026. Search concepts combined “chronic obstructive pulmonary disease, acute exacerbation or exacerbation-related care, cardiovascular events, myocardial infarction or acute coronary syndrome, heart failure, stroke, arrhythmia, cardiovascular mortality, and time-to-event terminology”. Records were de-duplicated before screening. Titles and abstracts were screened for temporal linkage between exacerbation and subsequent cardiovascular outcome. Reports were assessed in full text when they appeared to include adults with COPD, an exacerbation exposure, and a post-exacerbation cardiovascular outcome. Review articles, protocols, conference-only records without extractable data, studies without a post-exacerbation cardiovascular outcome, and biomarker-only or diagnostic-only studies were excluded from the primary clinical synthesis. Database-specific yields were PubMed (n=924), Embase (n=1,512), Scopus (n=1,546), and Web of Science (n=1,603). J.X. and R.M. independently screened titles and abstracts and assessed potentially eligible reports in full text; disagreements were resolved by discussion and re-examination of the source report. Complete database-specific search strategies are provided in Appendix 1, and database-specific record counts and PRISMA reconciliation are summarized in Table S1. Screening was intentionally conservative. Records were not included in the quantitative synthesis simply because they mentioned COPD and cardiovascular disease. To be eligible for primary synthesis, a report had to connect the exacerbation exposure to a subsequent cardiovascular outcome within an extractable time window. This avoided mixing prevalence of cardiovascular disease, diagnostic biomarkers, baseline comorbidity burden, or long-term prognosis with the acute post-exacerbation risk question. Outcomes and estimate hierarchy The primary outcome was a serious cardiovascular event or MACE-equivalent composite after COPD exacerbation. Where multiple estimates were available, one adjusted HR was selected per study and time window using a conservative hierarchy: adjusted models over crude estimates, serious nonfatal or cardiovascular-specific outcomes over all-cause composites when separable, 11–30-, 14–30-, or 15–30-day estimates over first-week-only estimates for the primary 30-day analysis, and non-overlapping populations where possible. This hierarchy was intended to reduce double counting and to prevent very early diagnostic overlap from dominating the 30-day estimate. This hierarchy was developed because the literature contains several non-exchangeable estimands. Some studies report myocardial infarction or stroke only, some report a composite of MACEs, some include heart failure or arrhythmia, and others include cardiovascular or all-cause mortality. Pooling all such estimates indiscriminately would give a larger apparent evidence base but a less interpretable result. The main model therefore sacrificed breadth for clinical coherence. The estimate-selection and synthesis safeguards are summarized in Table 1. Table 1Estimate-selection and synthesis safeguards used to reduce misleading poolingSafeguardReasonOne estimate per study per time windowPrevents within-study double counting and avoids overweighting multi-country study familiesAdjusted hazard ratios prioritizedKeeps the primary analysis closer to time-to-event cardiovascular risk and avoids mixing odds ratios with hazard ratiosSerious cardiovascular or MACE-equivalent outcomes prioritizedFocuses on clinically important events relevant to post-exacerbation safety reviewFirst-week estimates separatedPrevents the acute peak from defining the entire 30-day clinical interpretationPrediction intervals reportedShows whether the pooled hazard ratio is transferable across settings, not merely statistically significantNon-pooled studies mapped rather than forced into the modelPreserves clinical context while avoiding mathematically inappropriate poolingMACE, major adverse cardiovascular event. Estimate-selection and synthesis safeguards used to reduce misleading pooling MACE, major adverse cardiovascular event. Data extraction and risk-of-bias domains Extracted items included country or database, design, population, exacerbation definition, comparator, cardiovascular outcome, time window, effect measure, adjustment model, estimate, 95% confidence interval, and rationale for inclusion or non-pooling. Risk-of-bias domains were assessed using Newcastle-Ottawa Scale concepts for non-randomized studies, with emphasis on population selection, exposure ascertainment, outcome ascertainment, adjustment, and overlap between exposure and outcome windows. Because included designs varied substantially, risk-of-bias findings were used to guide interpretation rather than to exclude studies mechanically (23). J.X. and R.M. independently extracted data using a standardized form and independently assessed risk of bias; discrepancies were resolved by consensus after rechecking the source report. Detailed study characteristics and study-level risk-of-bias judgments are provided in Tables S2,S3, respectively. A structured non-pooled evidence map was maintained for studies that were clinically relevant but not statistically exchangeable with the primary adjusted-HR synthesis. These studies were used to identify recurring endpoint types, prognostic themes, biological support, and care-pathway implications, but they were not forced into the pooled model. This distinction is important because an apparently larger meta-analysis could be misleading if odds ratios, incidence-rate ratios, diagnostic biomarker studies, and heterogeneous outcome composites were combined as if they estimated the same parameter. The structured non-pooled evidence map, extracted effect estimates, pooled and sensitivity results, and full-text exclusion reasons are provided in Tables S4-S7, respectively. Statistical analysis HRs were log-transformed and standard errors were derived from 95% confidence intervals. Random-effects meta-analysis used restricted maximum likelihood with Hartung-Knapp adjustment (24). Analyses were conducted in R (25) using the metafor package (26). We report pooled HRs, 95% CIs, I2, tau2, Cochran Q, and 95% prediction intervals. Time-window analyses were performed for 1–7 days, 30 days or less, 31–90 days, and 181–365 days. A sensitivity analysis excluded the estimate restricted to the first week from the primary 30-day synthesis. Leave-one-study-out analyses tested whether a single study drove the early association. Prediction intervals were emphasized because they are more clinically informative than confidence intervals alone when heterogeneity is high. A confidence interval describes uncertainty around the mean effect, whereas a prediction interval estimates the range in which the effect of a similar future study might fall. For a question involving different countries, databases, exacerbation severities, and outcome definitions, this distinction is central to responsible interpretation. Formal tests for small-study effects were not performed because fewer than 10 studies contributed to the primary synthesis and substantial heterogeneity would limit interpretability. A formal GRADE certainty rating was not assigned; certainty was interpreted qualitatively using study design, risk of bias, consistency, precision, and transferability. A PRISMA items 17–19 support map is provided in Table S8. Results Study selection and evidence base Database searches identified 5,585 records. After removal of 1,915 duplicates, 3,670 records underwent title and abstract screening; 3,604 were excluded. Sixty-six reports were assessed in full text, 23 were excluded with reasons, and 43 studies were included in the systematic review. Ten studies contributed to at least one quantitative synthesis, and nine contributed to the primary 30-day serious cardiovascular event meta-analysis (Figure 1). The wider non-pooled evidence base contained direct post-exacerbation cardiovascular-risk studies with incompatible estimands, endpoint-specific studies, mortality or readmission models, biomarker or physiology studies, and care-pathway or burden studies. Study selection flow diagram. Records identified from PubMed, Embase, Scopus, and Web of Science were de-duplicated, screened, and assessed in full text. Forty-three studies were included in the systematic review; 10 contributed to any quantitative synthesis and 9 contributed to the primary meta-analysis. The final evidence base was recent and clinically diverse. It included post hoc trial analyses, population-based cohort studies, claims or electronic health record analyses, and multinational EXACOS-CV country cohorts. The non-pooled component was not discarded as irrelevant; rather, it was used to show that the cardiovascular signal is supported by multiple clinical designs even when only a smaller subset was appropriate for the strict primary synthesis. Detailed characteristics of all 43 included studies and the synthesis role of non-pooled studies are provided in Tables S2,S4. Across studies contributing to quantitative synthesis, overall risk of bias was generally low-to-moderate or moderate; recurring concerns included residual confounding, administrative-code definitions, endpoint heterogeneity, and structural similarity among related real-world data programs (Table S3). A single aggregate participant count was not calculated because several structurally related claims and electronic health record cohorts could overlap. Primary 30-day synthesis Nine studies contributed adjusted HRs for serious cardiovascular event or MACE-equivalent outcomes during the early post-exacerbation period. COPD exacerbation was associated with higher 30-day serious cardiovascular risk (pooled HR =2.38, 95% CI: 1.68–3.39). Statistical heterogeneity was high (I2=98.5%; tau2 =0.199), and the 95% prediction interval was wide (0.80–7.07), showing that the magnitude of risk is likely to differ across health-care settings and patient groups (Figure 2). Serious cardiovascular events within 30 days after acute exacerbation of chronic obstructive pulmonary disease. Forest plot of adjusted hazard ratios for serious cardiovascular event or MACE-equivalent outcomes. The primary analysis used one estimate per study and REML-HK. CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular event; REML-HK, restricted maximum likelihood with Hartung-Knapp adjustment. The individual study estimates were consistently above unity, but the magnitude varied widely. This pattern is clinically plausible: routine-care datasets may capture older and more comorbid patients than trial populations, severe or hospitalized exacerbations may carry higher absolute risk than outpatient-treated events, and outcome composites differ in the inclusion of heart failure, arrhythmia, stroke, myocardial infarction, pulmonary embolism, and cardiovascular death. For this reason, the pooled HR is best interpreted as evidence that a risk window exists, not as a bedside prediction rule. Time-windowed risk pattern The time-windowed analysis showed a steep early gradient (Figure 3). The 1-7-day window had the largest relative estimate (HR =12.53, 95% CI: 4.93–31.85; k =5), with very high heterogeneity and a wide prediction interval. For the primary 30-day-or-less window, risk remained increased (HR =2.38, 95% CI: 1.68–3.39; k =9). After removing the first-week-only estimate, the early association persisted (HR =2.13, 95% CI: 1.57–2.88; k =8). Later windows showed smaller but still elevated pooled estimates: 31–90 days (HR =1.56, 95% CI: 1.18–2.06; k =4) and 181-365 days (HR =1.38, 95% CI: 1.05–1.81; k =8). The pooled estimates across prespecified post-exacerbation time windows are summarized in Table 2. Time-stratified risk of serious cardiovascular events after acute exacerbation of chronic obstructive pulmonary disease. Pooled adjusted hazard ratios are shown across acute, early, intermediate, and late post-exacerbation windows. Black lines indicate 95% CIs; gray lines indicate 95% prediction intervals. The sensitivity estimate excludes estimates restricted to the first week only. CI, confidence interval; d, days; HR, hazard ratio. Table 2Time-stratified pooled estimates and clinical interpretationTime windowkPooled HR (95% CI)Prediction intervalI2Interpretation1–7 days512.53 (4.93–31.85)1.28–122.3599.7%Peak vulnerability; interpret cautiously because diagnostic overlap and severity effects are likely≤30 days, primary92.38 (1.68–3.39)0.80–7.0798.5%Main clinically actionable review window after exacerbation≤30 days, excluding first-week-only estimate82.13 (1.57–2.88)0.91–4.9596.4%Shows that the 30-day signal is not explained only by first-week estimates31–90 days41.56 (1.18–2.06)0.85–2.8883.6%Supports continued attention to cardiovascular stability after early recovery181–365 days81.38 (1.05–1.81)0.62–3.0797.5%Suggests a smaller sustained association that may reflect baseline disease and recurrent exacerbation riskCI, confidence interval; HR, hazard ratio. Time-stratified pooled estimates and clinical interpretation CI, confidence interval; HR, hazard ratio. The acute peak should be interpreted with particular caution. Very early cardiovascular events may reflect true triggering, diagnostic overlap, or both. For example, acute coronary syndrome, heart failure, pulmonary embolism, and arrhythmia can present with dyspnea and may initially be coded or treated as COPD exacerbation. The persistence of the association after exclusion of first-week-only estimates is therefore important because it supports a broader recovery-window signal beyond the most diagnostically ambiguous period. Sensitivity and transferability Leave-one-study-out analyses did not eliminate the early association; pooled estimates remained above 2.0 after sequential removal of individual studies. The most informative sensitivity result was the persistence of the 30-day association after separating the first-week-only estimate. Together with wide prediction intervals, this supports interpreting recent exacerbation as a risk-review trigger rather than as a fixed multiplier that can be applied uniformly to every patient. The complete leave-one-study-out analysis is shown in Figure S1. This sensitivity finding reduces concern that the main conclusion is an artifact of a single influential cohort. It does not remove concerns about between-study heterogeneity, but it supports the robustness of the direction of effect. In practical terms, the analysis argues for a consistent warning signal after exacerbation, while still requiring local clinical judgment about how aggressively to assess an individual patient. Discussion Principal findings This review found that cardiovascular risk after COPD exacerbation is strongly time dependent. The first week carried the largest relative risk, but a clinically important signal persisted through 30 days even after excluding the first-week-only estimate. Intermediate and later windows remained above unity, suggesting that exacerbation may be a marker of both acute instability and longer-term vulnerability. The central clinical message is therefore not that every patient has the same cardiovascular risk after exacerbation, but that the event itself should alert clinicians to a period in which cardiovascular review may be more useful. The results also help explain why previous broad summaries may be difficult to apply clinically. Combining very early and late estimates can obscure the short-term peak, whereas focusing only on the first week may overstate the risk that applies to the whole recovery period. The present time-stratified approach provides a more usable middle ground: it recognizes the acute peak but preserves a separate 30-day estimate that is more relevant to follow-up planning. Why this is useful for thoracic and respiratory practice The findings convert a diffuse comorbidity problem into a time-windowed safety problem. Respiratory and thoracic clinicians already review inhaled therapy, oxygenation, infection treatment, and recurrence prevention after an exacerbation. The present synthesis supports adding a low-burden cardiovascular check during the same recovery pathway, especially after severe or hospitalized exacerbations and in patients with known coronary disease, heart failure, arrhythmia, stroke risk, chest discomfort, syncope, persistent tachycardia, edema, troponin elevation, or unexplained dyspnea after treatment. This does not require routine escalation of antithrombotic or anti-inflammatory treatment for all patients. It supports selective reassessment, medication reconciliation, and referral or testing when clinical signals are present (27). A practical pathway does not need to be complex. At discharge or early follow-up, clinicians can identify high-risk features already available in routine care: severe or hospitalized exacerbation, known cardiovascular disease, advanced age, persistent hypoxemia, chest pain, palpitations, syncope, new edema, elevated troponin or natriuretic peptide when measured, and failure to return to baseline function. The review supports paying attention to these signals during the first week and the following month rather than waiting for overt cardiovascular decompensation. Interpreting high heterogeneity High heterogeneity is expected in this question because studies differ in comparator periods, health-care systems, exacerbation definitions, outcome composites, and baseline cardiovascular risk. The wide prediction intervals are therefore not a defect to hide; they define the limits of transferability. The pooled estimates identify the presence and timing of risk, whereas local clinical decisions should consider exacerbation severity, hospitalization, baseline cardiovascular disease, and diagnostic uncertainty. This distinction is important because the acute first-week peak may be affected by diagnostic overlap among COPD exacerbation, heart failure, acute coronary syndrome, pulmonary embolism, and arrhythmia. Why cardiovascular risk peaks early and declines over time The marked first-week peak is biologically plausible because an exacerbation simultaneously adds several transient triggers to a vulnerable cardiopulmonary substrate. Airway inflammation and infection can spill into the systemic circulation, while ventilation-perfusion mismatch, hypoxemia, hypercapnia, dynamic hyperinflation, and increased work of breathing raise sympathetic tone, heart rate, pulmonary vascular load, and myocardial oxygen demand. Endothelial dysfunction, platelet activation, and a hypercoagulable state may promote plaque disruption or thrombosis. Fluid shifts, beta2-agonist exposure, systemic corticosteroids, immobility, and interruption of chronic medications may further destabilize heart failure or arrhythmia. These mechanisms can coexist with diagnostic overlap because heart failure, acute coronary syndrome, pulmonary embolism, and arrhythmia can initially resemble acute exacerbation of COPD (6,7,28-37). Risk then declines as the acute respiratory and systemic insult resolves: oxygenation and ventilation improve, inflammatory and coagulation activity recede, adrenergic drive and myocardial oxygen demand fall, and patients resume mobility and chronic therapy. The decline is therefore compatible with attenuation of transient triggers rather than disappearance of baseline vulnerability. Residual excess risk through 30–90 days may reflect incomplete cardiopulmonary recovery, persistent inflammation or myocardial injury, deconditioning, recurrent exacerbations, and previously unrecognized cardiovascular disease. Thus, the temporal curve likely combines a sharp trigger effect with a slower return toward the patient’s underlying risk (28-37). Treatment and risk-reduction implications Treatment should address both the exacerbation and established cardiovascular disease. Acute management remains guideline-directed, including short-acting bronchodilators, a short course of systemic corticosteroids, antibiotics when indicated, controlled oxygen, and non-invasive ventilation when indicated. Ischemic heart disease, heart failure, arrhythmia, hypertension, dyslipidemia, and diabetes should be treated according to disease-specific guidelines (1,27). Early medication reconciliation is important because cardioselective beta-blockers, antiplatelet or anticoagulant therapy, statins, renin-angiotensin system inhibitors, and heart-failure therapies should not be withheld solely because of COPD when otherwise indicated. In selected frequent exacerbators, roflumilast or long-term azithromycin may reduce recurrent exacerbations but are not established as immediate cardiovascular prevention (38,39). This integrated respiratory-cardiovascular approach is consistent with recent mechanism-focused reviews and multidisciplinary consensus recommendations (40,41). Long-term COPD treatment should be optimized to prevent recurrent exacerbations. For patients with persistent exacerbations despite dual bronchodilation and an indication for an inhaled corticosteroid (ICS), triple therapy with ICS, a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) is recommended according to clinical phenotype, exacerbation history, and blood eosinophil count (1). In post hoc ETHOS analyses, budesonide/glycopyrrolate/formoterol reduced several cardiovascular and severe cardiopulmonary endpoints compared with LAMA/LABA dual therapy; a 2025 meta-analysis similarly found lower cardiovascular event risk versus LAMA/LABA but not a consistent advantage versus ICS/LABA (42,43). These findings are encouraging but do not prove that starting triple therapy immediately after an exacerbation prevents short-term cardiovascular events: cardiovascular outcomes were often secondary or post hoc, and the evidence applies mainly to patients with moderate-to-very severe COPD and prior exacerbations. Triple therapy should therefore be prescribed for established COPD indications, not solely as acute cardiovascular prophylaxis, with attention to ICS-associated pneumonia risk. Biological plausibility and translational implications Beyond these acute pathways, inflammatory evidence involving NLRP3-interleukin-1 signaling supports biological plausibility for a post-exacerbation inflammatory phenotype, but current data do not justify pathway-specific treatment recommendations after COPD exacerbation (28-37). Prospective studies should identify which patients have persistent inflammatory or myocardial-injury signals, when those signals peak, and whether targeted intervention improves outcomes. This interpretation is deliberately restrained. Anti-inflammatory cardiovascular trials and NLRP3-interleukin-1 biology are relevant to hypothesis generation, but the current COPD exacerbation literature is not sufficient to recommend colchicine, interleukin-1 blockade, NLRP3 inhibition, or other pathway-specific treatments after exacerbation outside established indications or clinical trials. The immediate implication is risk recognition and assessment, not automatic pharmacologic expansion. Strengths and limitations Strengths include a registered protocol, four-database search, explicit time-window hierarchy, restriction of the primary synthesis to adjusted HRs, separation of first-week and 30-day estimates, prediction intervals, leave-one-study-out analyses, and structured handling of non-pooled studies. Limitations are important. Most included evidence was observational or post hoc, outcome definitions were not identical, and many estimates came from claims or electronic health record data. Severity definitions varied, absolute risks could not be pooled reliably, and diagnostic overlap may inflate very early estimates. Structural similarity among EXACOS-CV country-specific cohorts increases consistency but also means that some estimates are not fully methodologically independent. For these reasons, the review should be interpreted as evidence for a time-sensitive clinical risk window, not as proof of one universal causal effect. Implications for practice and research For practice, the findings support a pragmatic pathway: identify patients recovering from moderate or severe COPD exacerbation; screen for cardiovascular symptoms and instability during the first week and, when clinically appropriate, again within 30 days; optimize existing cardioprotective therapies; and avoid dismissing persistent dyspnea, tachycardia, chest discomfort, edema, or functional decline as purely respiratory. For research, the next step is not another broad comorbidity summary. Future studies should harmonize exacerbation severity, baseline cardiovascular disease, cardiovascular endpoints, time windows, and absolute-risk reporting. Prospective studies should also test whether structured post-exacerbation cardiovascular assessment reduces events or readmissions. Future work should move from relative hazards toward absolute-risk tools. Clinicians need to know which patients have a sufficiently high short-term absolute risk to justify additional testing, cardiology referral, or structured follow-up. Harmonized reporting of baseline cardiovascular disease, exacerbation severity, medication use, biomarkers, and competing mortality would allow future analyses to move beyond broad risk windows and toward individualized post-exacerbation safety strategies. Conclusions Acute exacerbation of COPD marks a short-term cardiopulmonary risk window. Relative risk for serious cardiovascular events is highest in the first week, persists through 30 days, and remains detectable in later windows. Because heterogeneity and prediction intervals are substantial, recent exacerbation should be used as a practical trigger for targeted cardiovascular review rather than as a uniform risk multiplier or a basis for indiscriminate pharmacologic escalation. Supplementary The article’s supplementary files as